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Simple one/two step purification procedures based on the solid-phase extraction technique were effectively
exploited to clean up radiolabelled drugs represented by dihydrochloride of [6-3H]-stobadine and hydrochloride
of [4-3H]-pentacaine, derivatization agents such as 4-nitrobenzoyl chloride or 3,5-dinitrobenzoyl chloride, as well
as the aqueous phosphate or triethylamine acetate buffer solutions. © 1997 John Wiley & Sons, Ltd.
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INTRODUCTION
Today solid phase extraction (SPE) is a well established and
broadly exploited (pre-)separation technique (Manufac-
turers’ publications: Waters (1983); Analytichem
International (1987); Supelco (1988); Baker (1989); Varian
(1992); J. & W. Scientific Macherey-Nagel) in most
laboratories devoted to monitor the levels of various
compounds, e.g. therapeutic drugs, drugs of abuse, pollut-
ants, etc. By this procedure the substances of interest are
isolated from different matrices (biological fluids, animal/
plant tissues, water, soil, etc.), then usually concentrated,
and the level of the analytes is determined by a suitable
analytical method — chromatography, spectrometry, etc.
Thus on analysing such samples SPE, though inevitable,
serves as a co-procedure.
In the same laboratory, however, SPE can be used also as
the main step in preparing several (final, pure) materials of
interest. Such applications are shown below on the exam-
ples of purification of (A) the radiolabelled drugs
3H-stobadine and 3H-pentacaine in the mass quantity of
nanograms–micrograms, (B) the derivatization agents
4-nitrobenzoyl chloride and 3,5-dinitrobenzoyl chloride in
quantities of milligrams–grams and (C) aqueous buffer
solutions, components of the high-performance liquid
chromatographic (HPLC) mobile phases, in the volume
amount of millilitres–litres.
EXPERIMENTAL
Materials and chemicals. Standard SEP-PAK Silica and SEP-
PAK C18 cartridges were purchased from Waters Associates
(Milford, MA, USA). Separcol SI C18 (250 mg/3 mL) and empty
Separcol extraction columns were the products of the Anapron Co.
Ltd. (Bratislava, Slovak Republic). The latter were ‘home’ packed
with approximately 0.5 g of bare wideporous silicagel of BIO-
SPHER SI 300 (25 mm particles; LABIO Co., Prague, Czech
Republic) and subsequently cheap bovine serum albumin (BSA; A
9647; Sigma Chemical Co., St Louis, MO, USA) was in situ
adsorbed into the packing pores by the procedure described in the
literature (Erlandsson et al., 1986). Empty Separcol syringe barrels
were also packed with approximately 0.5 g of dried Na2SO4,
particle fraction 63–106 mm, i.e. 150–250 mesh (Lachema, Brno,
Czech Republic). CYCLOBOND I cartridges (500 mg/3 mL) used
were from ‘ASTEC’ — Advanced Separation Technologies Inc.
(Whippany, NJ, USA).
The dihydrochloride of [6-3H]-stobadine (I; Fig. 1) and
hydrochloride of [4-3H]-pentacaine (II; Fig. 1) used were both
partially decomposed as the consequence of a longer storage
period. The radiolabelled drugs, supplied in the form of methanolic
solutions by the Institute for Research, Production, and Uses of
Radioisotopes, Prague, Czech Republic, had originally the follow-
ing radiochemical parameters: I, purity >98%; activity,
40 MBq/mL; specific activity, 495 GBq/mM; II, purity >96%;
activity 80 MBq/mL; specific activity 48 GBq/mM.
The stocks of 4-nitrobenzoyl chloride (4-NBC), C7H4ClNO3
(Fluka Chemie, Neu-Ulm, Germany) and 3,5-dinitrobenzoyl
chloride (3,5-DNBC), C7H3ClN2O5 (Regis Chemical Co., Morton
Grove, IL, USA) used were partially decomposed during their
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Figure 1. Chemical structures of dihydrochloride of stobadine
(I) and hydrochloride of pentacaine (II). (The asterisks indicate
the position of the tritium atom in the radiolabelled com-
pounds.)
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storage by the action of daylight and atmospheric humidity.
Na2HPO4 312 H2O and KH2PO4 of p.a. purity grade (Merck,
Darmstadt, Germany), triethylamine (TEA; Fluka Chemie), and
glacial acetic acid (Lachema) served as the HPLC mobile phase
buffering components. Phosphate buffer of ‘physiological compo-
sition’ was prepared by mixing the aqueous Na2HPO4 and KH2PO4
solutions (each 0.067 mol/L) in the volume ratio of 80.3:19.7 (pH
7.4). Triethylamine acetate (TEAAc) buffer was prepared by
titrating the 0.1% aqueous solution of TEA with glacial acetic acid
up to the desired pH value (usually 4.1).
Water, CH3CN, and CH3OH of HPLC purity grade were
purchased from J. T. Baker Chemical Co., Phillipsburg, NJ, USA.
CH2Cl2 (Koch-Light Laboratories Ltd., Colnbrook, England) and
cyclohexane p.a. (Lachema), each approximately 20 mL, were
dried immediately before use by their filtration through the Na2SO4
bed held in the Separcol columns.
Procedure A1. The methanolic solution (0.1–1.0 mL) of di-
hydrochloride of [6-3H]-stobadine was diluted by distilled water to
the final CH3OH concentration of 20% or less. This working
solution was then run through the sorbent bed of the pre-
conditioned (2 mL CH3OH, 2 mL H2O) Separcol SI C18. The
sample components trapped by the extraction column packing
were subsequently washed with 2 mL of pure acetonitrile. The
trapped substance I was flushed out/displaced from the column by
applying 1.0 mL of methanol. The radiochemical purity of the
recovered dihydrochloride of [6-3H]-stobadine was determined by
means of thin-layer chromatography (Šoltés and Trnovec, 1987)
and/or an HPLC method (Ščasnár et al., 1989).
Procedure A2. A procedure analogous to that of A1 was applied on
purifying hydrochloride of [4-3H]-pentacaine. In this case, instead
of the Separcol SI C18 column the SEP-PAK C18 cartridge was
applied advantageously (Šoltés et al., 1983). The purified drug —
II — was collected as the fraction eluted between 0.5–2.5 mL (Fig.
2). The radiochemical purity of hydrochloride of [4-3H]-pentacaine
was determined by the method of Ščasnár et al. (1984).
Procedure B1. 4-NBC, 0.2 g (light-brownish powder) was dis-
solved in 2 mL of dry CH2Cl2. Next 8 mL of dry cyclohexane was
added into this solution to weaken the solvent polarity. The final
sample solution was then pressed through the SEP-PAK Silica
cartridge (flow rate approximately 1–2 mL/min). By such a
treatment the dark-brownish sample component(s) remained
trapped at the top of the sorbent bed, while a light-yellow solution
passed unretained through the cartridge. Subsequent crystallization
— CH2Cl2 evaporation — yielded clear yellow needles (67%). The
melting point (m.p.) was 74–75°C. The elemental C:H:N analysis
was: theoretical, 45.31:2.17:7.55; found, 45.10:2.29:7.60.
Procedure B2. A treating procedure analogous to that of B1 was
successfully used also to purify the sample of 3,5-DNBC. The
yield of the dark yellow crystalline material was 88% with a m.p.
of 69–70°C. The elemental C:H:N analysis was: theoretical,
36.41:1.31:12.15; found, 36.20:1.38:12.20. (The recovered materi-
als had identical physico-chemical parameters — IR (KBr disc);
MS; and H-/C-NMR spectra — with those reported for the
chemically pure 4-nitrobenzoyl chloride and 3,5-dinitrobenzoyl
chloride.)
Procedure C1. The freshly prepared aqueous phosphate buffer
(0.2–1.0 L), used at the chiral HPLC analysis on working with the
BSA-bond column (Šoltés et al., 1994; Šoltés, L., and Sébille, B.
unpublished data), was clarified by its fast running (approximately
20 mL/min) through the barrel of the BSA modified Separcol silica
minocolumn.
Procedure C2. The TEAAc buffer (up to 1.0 L), preferably used
for chiral HPLC at working with the cyclodextrin-bond columns in
aqueous media, was cleansed by a procedure analogous to that of
C1. To trap the impurities from the aqueous TEAAc buffer
solution, the cartridge of CYCLOBOND I was here exploited
effectively.
Figure 2. Cumulative elution of the hydrochloride of [4-3H]-pentacaine from the SEP-PAK C18
cartridge by the weak solvents aqueous methanol — H2O:CH3OH, 80:20, v/v (1) and acetonitrile
(2), and by strong methanol (3).
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RESULTS AND DISCUSSION
Procedures A
Radiolabelled substances are broadly used in biomedical
research. In determining the experimental pharmacokinetics
of a new drug, the required tracer purity is >95%. If
decomposition occurring during sample storage reduces the
content of the radiolabelled drug, the tracer has to be
cleansed. Since labelled substances are usually charac-
terized by high specific activity, their cleansing should yield
only a minimal volume of waste. The use of extraction in
the system of two liquids (liquid–liquid extraction — LLE)
appears to be a priori questionable as LLE operates mostly
with large volumes (tens to hundreds of millilitres) of
aqueous/non-aqueous solutions. On the other hand, exploi-
tation of SPE cartridges for the purification of isotopically
labelled substances can be characterized as a particularly
appropriate alternative. Compared to LLE, SPE provides the
advantage (i) that the volumes of liquids which are
eventually wasted are small, and (ii) that the small corpus of
the cartridge allows its safe long-term storage.
In our case, fractional cleaning of tracers I/II by
procedures A1/A2 resulted essentially in the following four
low-volume fractions: (1) the ‘original’ aqueous–metha-
nolic (volume <1.0 mL); (2) the acetonitrilic wash (Šoltés,
1992) (volume 2 mL); (3) the recovered methanolic eluate
(1.0 mL) containing the purified substance I/II, and (4) the
‘contaminated’ SPE cartridge. Should subsequent checking
of the radiochemical purity of dihydrochloride of [6-3H]-
stobadine or of hydrochloride of [4-3H]-pentacaine still
detect an inadequate purity grade, the solid and liquid waste
obtained by using procedures A1/A2 presents an acceptable
material of a volume below 10 mL, which can easily be
stored over a long period of time.
Procedures B
The derivatization agents 4-nitrobenzoyl chloride and
3,5-dinitrobenzoyl chloride are highly reactive substances
which react very readily with alcohols, phenols, as well as
primary and secondary amines (Manufacturer’s publication:
Regis Chemical Co). Thus due to the action of air humidity,
gradual decomposition of the substance sets in at each
opening of the storage jar. The reaction products can
subsequently undergo further decomposition effected by
heat, light, and also as a consequence of their reaction with
the parent 4-NBC and 3,5-DNBC. Effective derivatization,
however, requires a reagent of the purest quality to warrant
one single resulting derivative with defined properties.
The SPE technique of purification of the given derivatiza-
tion substances developed is based on the precondition that
in the course of their reaction with H2O vapors both 4-NBC
and 3,5-DNBC are most probably contaminated by sub-
stances of higher polarity. Owing to the higher affinity of
the latter to silica gel, these products can be separated from
the molecules of the parent derivatization agent by exploit-
ing, for example, the commercial SEP-PAK silica cartridge.
The two-component liquid phase used (cyclohexane:CH2Cl2
80:20, v/v) proved to be particularly appropriate, though
only for the elution of the purified substance (4-NBC,
3,5-DNBC), while its decomposition products remained
trapped on the cartridge top. By the subsequent evaporation
of the substantially more evaporative CH2Cl2 (Manu-
facturer’s publication, Spectra-Physics) (boiling point (b.p.)
39.8°C), the purified 4-NBC or 3,5-DNBC (both substances
are relatively poorly soluble in cyclohexane — b.p. 80.7°C)
crystallize in the form of clear yellow needles.
Procedures C
On using aqueous chiral HPLC, both the ionic strength and
the pH value of the mobile phase are set by adding inorganic
or polar organic buffers, which should be substances of
highest purity. Yet, as mentioned also in the literature
(Manufacturer’s Publication: Advanced Separation Technol-
ogies Inc.; Šoltés et al., 1994, 1996; Šoltés, L. and Sébille,
B., unpublished data), even some substances of declared
p.a. quality contain impurities strongly adsorbing to the
chiral stationary phase and thus gradually diminishing the
resolution of the method. The suggested use of a guard
precolumn with a chiral sorbent identical with that con-
tained in the analytical column does present a certain
solution, nevertheless pre-purification of the mobile phase is
of advantage in any case.
Our approach, i.e. the application of SPE cartridges,
removed most impurities both from the aqueous phosphate
and the TEAAc buffer, which would have gradually blocked
the chiral precolumn/column used. Although the purifica-
tion of the mobile phase is time-consuming, the cost of the
required disposable cartridges is low, so that the approach
proves to be ultimately cost-effective, considering the
relatively expensive chiral BSA-bond/CYCLOBOND I
guard and/or analytical column(s).
CONCLUSION
As demonstrated on the examples given, the SPE purifica-
tion technique presented can be assessed as both quality-
and cost-effective.
Acknowledgements
The authors are greatly indebted to the Grant Agency for Sciences,
Bratislava, Slovak Republic for the GAS 1021 and the EUREKA S-9039
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